Core Viewpoint - FedEx (FDX.US) shares rose over 3%, reaching a record high of $378.75, driven by strong earnings expectations and ambitious financial targets for fiscal year 2029 [1] Financial Performance - FedEx anticipates adjusted earnings of $3.99 for the third fiscal quarter ending in February, surpassing market expectations [1] Future Financial Goals - The company has set financial targets for fiscal year 2029, including consolidated revenue of $98 billion, operating income of $8 billion, and an operating margin of 8% [1]

Core Insights - Zoetis (ZTS) has a strong history of beating earnings estimates and is well-positioned for future earnings growth [1][5] - The company has surpassed earnings estimates by an average of 7.18% over the last two quarters [1][5] - The upcoming earnings report is expected on November 4, 2025 [8] Earnings Performance - For the last reported quarter, Zoetis achieved earnings of $1.76 per share, exceeding the Zacks Consensus Estimate of $1.62 per share by 8.64% [2] - In the previous quarter, the company reported earnings of $1.48 per share against an expectation of $1.4 per share, resulting in a surprise of 5.71% [2] Earnings Estimates and Predictions - Estimates for Zoetis have been trending higher, supported by its history of earnings surprises [5] - The company currently has an Earnings ESP of +0.41%, indicating a positive outlook from analysts regarding its earnings prospects [8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat [8][6]

Core Insights - ResMed is positioned to continue its earnings-beat streak, having surpassed earnings estimates in the last two quarters by an average of 3.04% [1][5] - The company reported earnings of $2.36 per share for the most recent quarter, slightly below the expected $2.37, but still achieved a surprise of 0.42% [2] - In the previous quarter, ResMed exceeded the consensus estimate of $2.30 per share by reporting $2.43, resulting in a surprise of 5.65% [2] Earnings Estimates and Predictions - Recent estimates for ResMed have been increasing, with a positive Earnings ESP of +5.16%, indicating bullish sentiment among analysts regarding the company's earnings prospects [5][8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data showing that such combinations lead to positive surprises nearly 70% of the time [6][8] Earnings ESP Explanation - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7] - A negative Earnings ESP can reduce predictive power but does not necessarily indicate an earnings miss [9] Importance of Earnings ESP - Companies often beat consensus EPS estimates, but this is not the only factor influencing stock price movements; thus, checking the Earnings ESP is crucial for investment decisions [10]